NO_LONGER_AVAILABLENCT03642691
A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial
Studying Hypoplasminogenemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Prometic Biotherapeutics, Inc.
- Principal Investigator
- Jeremy Lorber, MDTower Hematology, Oncology
- Intervention
- Ryplazim(biological)
- Eligibility
- All sexes
Study locations (3)
- Tower Hematology and Oncology, Beverly Hills, California, United States
- Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03642691 on ClinicalTrials.govOther trials for Hypoplasminogenemia
Additional recruiting or active studies for the same condition.